Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
18 Results for "
sumoylation
" in MedChemExpress (MCE) Product Catalog:
Products (18)
18 Results for "sumoylation" in MCE Product Catalog:
34
34 Publications Verification
Synonyms: TAK-981
Target:
Research Areas:
Subasumstat (TAK-981) is a first in class and selective inhibitor of the SUMOylation enzymatic cascade, with potential immune-activating and antineoplastic activities .
17
Category:
Ginkgoaceae Plants Ginkgo biloba Monophenols Simple Phenylpropanols Ketones, Aldehydes, Acids Phenols Phenylpropanoids Disease Research Fields Cancer
Target:
12
12 Cited Publications
Target:
Research Areas:
2-D08 is a cell permeable, mechanistically unique inhibitor of protein SUMOylation. 2-D08 also inhibits Axl with an IC50 of 0.49 nM.
2
2 Cited Publications
Target:
Research Areas:
N106 is a first-in-class sarcoplasmic reticulum calcium ATPase (SERCA2a) SUMOylation activator. N106 directly activates the SUMO-activating enzyme, E1 ligase. N106 can be used for heart failure research .
2
2 Cited Publications
Target:
Research Areas:
COH000 is an allosteric, covalent and irreversible inhibitor of ubiquitin-like 1-activating enzyme (SUMO-activating enzyme) (E1), with an IC50 of 0.2 μM for SUMOylation in vitro .
Cat. No.: HY-Y0493
CAS No.: 28230-32-2
Synonyms: HOOBt
HODHBt (HOOBt) inhibits STAT5-SUMO interaction by blocking SUMOylation of phosphorylated STAT5. HODHBt enhances the magnitude of IL-15 signaling and significantly increases the natural killer (NK) cell cytotoxicity phenotype and function and the generation of cytokine-induced memory-like (CIML) natural killer (NK) cells. HODHBt can be used for research of HIV-infection and cancer .
Target:
Research Areas:
Target:
Research Areas:
AZ194 is a first-in-class, orally active inhibitor of CRMP2-Ubc9 interaction and inhibitor of NaV1.7 (IC50=1.2 μM). AZ194 blocks SUMOylation of CRMP2 to selectively reduce the amount of surface-expressed NaV1.7. Antinociceptive effects .
Synonyms: (S)-TAK-981
Target:
Research Areas:
(S)-Subasumstat is the isomer of Subasumstat (HY-111789). Subasumstat (TAK-981) is a first in class and selective inhibitor of the SUMOylation enzymatic cascade, with potential immune-activating and antineoplastic activities .
Cat. No.: HY-123888
CAS No.: 55625-78-0
Category:
Target:
Cat. No.: HY-176907
CAS No.: 1858275-91-8
Target:
Research Areas:
ML-93 is an orally active SAE inhibitor, with an IC50 value of 0.4 μM. ML-93 inhibits the SUMOylation pathway in HCT116 cells. ML-93 shows robust antitumor activity in the HCT116 colorectal carcinoma xenograft model. ML-93 can be used for the study of colorectal cancer .
Cat. No.: HY-N0077R
CAS No.: 22910-60-7
Synonyms: Ginkgolic acid (15:1) (Standard); Ginkgolic acid I (Standard); Romanicardic acid (Standard)
Target:
Cat. No.: HY-148835A
Purity: 99.77%
Target:
Research Areas:
Cat. No.: HY-145269
CAS No.: 2761538-66-1
AL-GDa62 is a derivative of the CDH1/E-cadherin modulator SLEC-11 (HY-145268) and induces apoptosis in CDH1 -/- cells. AL-GDa62 has an EC50 of 3.2 μM and 2 μM for isogenic mammary epithelial cells MCF10A-WT (wild type) and mutant MCF10A-CDH1 -/-, respectively. AL-GDa62 specifically inhibits TCOF1, ARPC5, and UBC9, and suppresses SUMOylation at low micromolar concentrations .
Cat. No.: HY-181772
CAS No.: 315698-78-3
Target:
Research Areas:
MCULE-3064932370 is a covalent and allosteric SUMO E1 (heterodimer of Aos1 and Uba2) inhibitor with IC50 values ranging from 16.66 μM to 2.96 μM. MCULE-3064932370 inhibits SUMOylation of Uba2. MCULE-3064932370 has anti-cancer activity against breast cancer .
Cat. No.: HY-148269
CAS No.: 2025371-99-5
AN13762 is a benzoxaborole antimalarial agent. AN13762 augments Plasmodium falciparum stress responses. AN13762 acts against cultured and fresh Plasmodium falciparum isolates and in vivo murine malaria models. AN13762 can be used for the research of malaria .
Cat. No.: HY-L024
920 compounds
A histone modification, a covalent post-translational modification (PTM) to histone proteins, includes methylation, phosphorylation, acetylation, ubiquitylation, and sumoylation, etc. In general, histone modifications are catalyzed by specific enzymes that act predominantly at the histone N-terminal tails involving amino acids such as lysine or arginine, as well as serine, threonine, tyrosine, etc. The PTMs made to histones can impact gene expression by altering chromatin structure or recruiting histone modifiers. Histone modifications act in diverse biological processes such as transcriptional activation/inactivation, chromosome packaging, and DNA damage/repair. Deregulation of histone modification contributes to many diseases, including cancer and autoimmune diseases.
MCE owns a unique collection of 920 bioactive compounds targeting Epigenetic Reader Domain, HDAC, Histone Acetyltransferase, Histone Demethylase, Histone Methyltransferase, Sirtuin, etc. Histone Modification Research Compound Library is a useful tool for histone modification research and drug screening.
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
